JP2020117553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020117553A5 JP2020117553A5 JP2020086708A JP2020086708A JP2020117553A5 JP 2020117553 A5 JP2020117553 A5 JP 2020117553A5 JP 2020086708 A JP2020086708 A JP 2020086708A JP 2020086708 A JP2020086708 A JP 2020086708A JP 2020117553 A5 JP2020117553 A5 JP 2020117553A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cobicistat
- drug
- vincristine
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 67
- 206010028980 Neoplasm Diseases 0.000 claims 47
- 201000011510 cancer Diseases 0.000 claims 46
- 229940041181 antineoplastic drug Drugs 0.000 claims 42
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims 37
- 229960002402 cobicistat Drugs 0.000 claims 37
- 229960004528 vincristine Drugs 0.000 claims 24
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical group C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 24
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 23
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 21
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 21
- 206010006187 Breast cancer Diseases 0.000 claims 18
- 208000026310 Breast neoplasm Diseases 0.000 claims 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 18
- 208000000453 Skin Neoplasms Diseases 0.000 claims 18
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 18
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 18
- 201000010536 head and neck cancer Diseases 0.000 claims 18
- 208000014829 head and neck neoplasm Diseases 0.000 claims 18
- 201000005202 lung cancer Diseases 0.000 claims 18
- 208000020816 lung neoplasm Diseases 0.000 claims 18
- 201000000849 skin cancer Diseases 0.000 claims 18
- 201000002510 thyroid cancer Diseases 0.000 claims 18
- 206010046766 uterine cancer Diseases 0.000 claims 18
- 206010008342 Cervix carcinoma Diseases 0.000 claims 17
- 206010033128 Ovarian cancer Diseases 0.000 claims 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 17
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 17
- 201000010881 cervical cancer Diseases 0.000 claims 17
- 201000003733 ovarian melanoma Diseases 0.000 claims 17
- 201000008017 ovarian lymphoma Diseases 0.000 claims 16
- 206010009944 Colon cancer Diseases 0.000 claims 15
- 208000029742 colonic neoplasm Diseases 0.000 claims 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 14
- 201000002528 pancreatic cancer Diseases 0.000 claims 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 14
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 12
- 230000001965 increasing effect Effects 0.000 claims 12
- 229960003048 vinblastine Drugs 0.000 claims 12
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 12
- 230000004060 metabolic process Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371105P | 2016-08-04 | 2016-08-04 | |
| US62/371,105 | 2016-08-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505383A Division JP6764017B2 (ja) | 2016-08-04 | 2017-08-01 | がんの処置での使用のためのコビシスタット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170294A Division JP2021001235A (ja) | 2016-08-04 | 2020-10-08 | がんの処置での使用のためのコビシスタット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020117553A JP2020117553A (ja) | 2020-08-06 |
| JP2020117553A5 true JP2020117553A5 (enExample) | 2020-12-24 |
Family
ID=59579948
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505383A Active JP6764017B2 (ja) | 2016-08-04 | 2017-08-01 | がんの処置での使用のためのコビシスタット |
| JP2020086708A Withdrawn JP2020117553A (ja) | 2016-08-04 | 2020-05-18 | がんの処置での使用のためのコビシスタット |
| JP2020170294A Withdrawn JP2021001235A (ja) | 2016-08-04 | 2020-10-08 | がんの処置での使用のためのコビシスタット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505383A Active JP6764017B2 (ja) | 2016-08-04 | 2017-08-01 | がんの処置での使用のためのコビシスタット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170294A Withdrawn JP2021001235A (ja) | 2016-08-04 | 2020-10-08 | がんの処置での使用のためのコビシスタット |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180036289A1 (enExample) |
| EP (1) | EP3493797A1 (enExample) |
| JP (3) | JP6764017B2 (enExample) |
| AU (2) | AU2017305303B2 (enExample) |
| CA (1) | CA3032813A1 (enExample) |
| MA (1) | MA45848A (enExample) |
| TW (2) | TWI718327B (enExample) |
| WO (1) | WO2018026835A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI705813B (zh) * | 2019-05-24 | 2020-10-01 | 國立交通大學 | 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途 |
| MX2022000082A (es) * | 2019-06-21 | 2022-06-16 | Pattern Computer Inc | Composiciones terapeuticas y metodos para tratar canceres. |
| US20230029486A1 (en) * | 2020-01-10 | 2023-02-02 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
| US20230174649A1 (en) * | 2020-04-30 | 2023-06-08 | I-Mab Biopharma Us Limited | Pharmaceutical compositions containing anti-cd47 antibodies |
| WO2021231611A1 (en) * | 2020-05-12 | 2021-11-18 | Splash Pharmaceuticals, Inc. | Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status |
| CN114762691A (zh) * | 2021-01-12 | 2022-07-19 | 中国科学院上海药物研究所 | 双嘧达莫在抗肿瘤中的应用 |
| CN113577304B (zh) * | 2021-07-26 | 2023-12-26 | 深圳市泰尔康生物医药科技有限公司 | 一种针对乳腺癌her2靶点的多肽偶联药物的开发及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
| HRP20161751T1 (hr) | 2004-05-13 | 2017-04-07 | Icos Corporation | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| SI2049506T2 (sl) | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| ES2779826T3 (es) * | 2007-02-23 | 2020-08-20 | Gilead Sciences Inc | Moduladores de propiedades farmacocinéticas de agentes terapéuticos |
| EP2185198B1 (en) | 2007-08-02 | 2015-01-14 | Gilead Biologics, Inc. | Lox and l0xl2 inhibitors and uses thereof |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| RU2015108348A (ru) | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| NZ701444A (en) | 2010-08-27 | 2016-06-24 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| JP6101205B2 (ja) | 2011-08-23 | 2017-03-22 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| JP2014528451A (ja) | 2011-10-04 | 2014-10-27 | ギリアード カリストガ エルエルシー | Ｐｉ３ｋの新規キノキサリン阻害剤 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| TW201427995A (zh) | 2012-09-24 | 2014-07-16 | Gilead Sciences Inc | 抗ｄｄｒ１抗體 |
| CA2895782C (en) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| EP2935246B1 (en) | 2012-12-21 | 2018-07-25 | Gilead Calistoga LLC | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| JP2016512549A (ja) * | 2013-03-14 | 2016-04-28 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ |
| PL3008053T3 (pl) | 2013-06-14 | 2018-08-31 | Gilead Calistoga Llc | Inhibitory 3-kinazy fosfatydyloinozytolu |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2016138542A1 (en) * | 2015-02-28 | 2016-09-01 | Cyprus Therapeutics, Inc. | Methods for inhibiting tumors and drug resistance |
| CN114177180A (zh) * | 2015-08-27 | 2022-03-15 | 北京美倍他药物研究有限公司 | 依鲁替尼的药物组合物 |
-
2017
- 2017-08-01 CA CA3032813A patent/CA3032813A1/en not_active Abandoned
- 2017-08-01 AU AU2017305303A patent/AU2017305303B2/en active Active
- 2017-08-01 JP JP2019505383A patent/JP6764017B2/ja active Active
- 2017-08-01 US US15/666,417 patent/US20180036289A1/en not_active Abandoned
- 2017-08-01 WO PCT/US2017/044932 patent/WO2018026835A1/en not_active Ceased
- 2017-08-01 EP EP17751204.3A patent/EP3493797A1/en not_active Withdrawn
- 2017-08-01 MA MA045848A patent/MA45848A/fr unknown
- 2017-08-04 TW TW106126377A patent/TWI718327B/zh not_active IP Right Cessation
- 2017-08-04 TW TW110103932A patent/TW202123943A/zh unknown
-
2020
- 2020-05-18 JP JP2020086708A patent/JP2020117553A/ja not_active Withdrawn
- 2020-07-28 AU AU2020210188A patent/AU2020210188A1/en not_active Abandoned
- 2020-10-08 JP JP2020170294A patent/JP2021001235A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020117553A5 (enExample) | ||
| Ferris et al. | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | |
| Petrella et al. | Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| Yeung et al. | Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model | |
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2018508516A5 (enExample) | ||
| Budde et al. | A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma | |
| JP2014511383A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| Beer et al. | Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel | |
| JP2019524888A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| MX2024007749A (es) | Formulaciones clinicas de anticuerpos anti-tigit. | |
| JP2015510945A5 (enExample) | ||
| JP2018522881A5 (enExample) | ||
| SA94140746B1 (ar) | مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان | |
| Aggarwal et al. | Aripiprazole lauroxil long-acting injectable: the latest addition to second-generation long-acting agents | |
| Brunsvig et al. | Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years’ follow-up | |
| Tseng et al. | Magnolol’s Therapeutic Efficacy and Immunomodulatory Effects in Oral Squamous Cell Carcinoma | |
| Basu et al. | Is interferon-α and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix? | |
| Teng et al. | Nimotuzumab and irinotecan synergistically induce ROS‐mediated apoptosis by endoplasmic reticulum stress and mitochondrial‐mediated pathway in cervical cancer | |
| CN105079149A (zh) | 小金丸在制备治疗多发性骨髓瘤药物中的应用 | |
| Berkson et al. | A review of the integrative treatment approach using the intravenous alpha-lipoic acid/low dose naltrexone (ALA/N) protocol for cancer and a description of the long-term survival of a woman with hepatocellular carcinoma |